Tissue-agnostic oncology offers new hope for patients with rare cancers — but only if we rethink how we test, treat and trial. In this op-ed, TRACER Director Taran Gujral, PhD, urges a shift toward biology-driven care, flexible trial design and broader access to molecular testing. When treatment is guided by how a tumor behaves instead of where it starts, rarity becomes a catalyst for innovation.
Read the full story here: